SE0103272D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0103272D0
SE0103272D0 SE0103272A SE0103272A SE0103272D0 SE 0103272 D0 SE0103272 D0 SE 0103272D0 SE 0103272 A SE0103272 A SE 0103272A SE 0103272 A SE0103272 A SE 0103272A SE 0103272 D0 SE0103272 D0 SE 0103272D0
Authority
SE
Sweden
Prior art keywords
compounds
solvates
pharmaceutically acceptable
carboxypeptidase
chemical compounds
Prior art date
Application number
SE0103272A
Other languages
English (en)
Swedish (sv)
Inventor
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103272A priority Critical patent/SE0103272D0/xx
Publication of SE0103272D0 publication Critical patent/SE0103272D0/xx
Priority to US10/489,530 priority patent/US7375121B2/en
Priority to JP2003530715A priority patent/JP2005503442A/ja
Priority to DE60233578T priority patent/DE60233578D1/de
Priority to EP02770366A priority patent/EP1432718B1/fr
Priority to PCT/SE2002/001737 priority patent/WO2003027128A1/fr
Priority to AT02770366T priority patent/ATE441653T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/5765Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0103272A 2001-09-28 2001-09-28 Chemical compounds SE0103272D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0103272A SE0103272D0 (sv) 2001-09-28 2001-09-28 Chemical compounds
US10/489,530 US7375121B2 (en) 2001-09-28 2002-09-23 Chemical compounds
JP2003530715A JP2005503442A (ja) 2001-09-28 2002-09-23 化学化合物
DE60233578T DE60233578D1 (de) 2001-09-28 2002-09-23 Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
EP02770366A EP1432718B1 (fr) 2001-09-28 2002-09-23 Composés contenant du phosphore et ayant une activité antithrombotique
PCT/SE2002/001737 WO2003027128A1 (fr) 2001-09-28 2002-09-23 Composes chimiques
AT02770366T ATE441653T1 (de) 2001-09-28 2002-09-23 Phosphorenthaltende verbindugnen mit antithrombitische wirkung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103272A SE0103272D0 (sv) 2001-09-28 2001-09-28 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0103272D0 true SE0103272D0 (sv) 2001-09-28

Family

ID=20285515

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103272A SE0103272D0 (sv) 2001-09-28 2001-09-28 Chemical compounds

Country Status (7)

Country Link
US (1) US7375121B2 (fr)
EP (1) EP1432718B1 (fr)
JP (1) JP2005503442A (fr)
AT (1) ATE441653T1 (fr)
DE (1) DE60233578D1 (fr)
SE (1) SE0103272D0 (fr)
WO (1) WO2003027128A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528173B2 (en) * 2002-03-21 2009-05-05 Schering Aktiengesellshaft Plasma carboxypeptidase B inhibitors
WO2010050525A1 (fr) 2008-10-29 2010-05-06 大正製薬株式会社 Composé ayant une activité inhibitrice des tafia
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
SE9901572D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
AR023819A1 (es) 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP3400798B2 (ja) 1999-09-14 2003-04-28 明治製菓株式会社 カルボキシペプチダーゼb阻害活性を有するホスホン酸誘導体
PT1311488E (pt) 2000-08-17 2009-12-30 Pfizer Ltd Imidazóis substituídos utilizados como inibidores de tafia

Also Published As

Publication number Publication date
EP1432718B1 (fr) 2009-09-02
WO2003027128A1 (fr) 2003-04-03
US7375121B2 (en) 2008-05-20
DE60233578D1 (de) 2009-10-15
EP1432718A1 (fr) 2004-06-30
US20040248852A1 (en) 2004-12-09
ATE441653T1 (de) 2009-09-15
JP2005503442A (ja) 2005-02-03

Similar Documents

Publication Publication Date Title
SE9901573D0 (sv) New compounds
SE0202462D0 (sv) Novel use
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
ZA200501098B (en) Novel use of benzothiazole derivatives
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
GB0112348D0 (en) Compounds
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
SE0002476D0 (sv) New compounds
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE9901572D0 (sv) New compounds
WO2002064552A8 (fr) DERIVE DE α-AMINO-N-HYDROXY-ACETAMIDE
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
SE0103272D0 (sv) Chemical compounds
SE9900190D0 (sv) New compounds
MA27157A1 (fr) Methode de traitement d'affections osseuses.
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
EP1291349A4 (fr) Derives de malto-oligosaccharide et utilisation correspondante
DE60022047D1 (de) Antivirale therapie
SE0301904D0 (sv) Novel imidazopyridine compound II with therapeutic effect
DE60104288D1 (de) Antivirale therapie
PT1370526E (pt) Diamidas que inibem a actividade da triptase e do factor xa